# Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

> **NCT02501811** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 125 (actual)

## Conditions studied

- Ischemic Cardiomyopathy

## Interventions

- **BIOLOGICAL:** Mesenchymal Stem Cells (MSC)
- **BIOLOGICAL:** c-kit+ cells
- **BIOLOGICAL:** Placebo (Plasmalyte A)

## Key facts

- **NCT ID:** NCT02501811
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2020-06-25
- **Final completion:** 2020-07-22
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2021-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501811, "Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02501811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*